Now accepting early access partners

Validation that moves
at the speed of science.

EVOLV | The Validation Factory

The first AI-native Computer System Validation platform built for GAMP 5, 21 CFR Part 11, and FDA QMSR. Generate compliant URS, automate risk assessment, and govern AI model changes — in minutes, not months.

Request Early Access ▶ Try Live Demo
GAMP 5 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 2025 GMP Annex 11 EU GMP

The Problem

CSV validation still runs on
spreadsheets and email chains.

Life sciences teams spend months on documentation that should take days. Regulatory guidance has changed. Most platforms haven't.

📋

Weeks to generate a URS

Requirements written manually in Word, reviewed in meetings, rewritten after audit findings. No regulatory traceability. No version control. Just documents.

⚠️

Regulations change. VMPs don't.

FDA's QMSR replaced the QSR on February 2, 2026. The PCCP final guidance landed August 2025. Most validation plans still cite rules that no longer exist.

🤖

AI in GxP with no governance

Drug interaction predictors and defect classifiers are being deployed with no PCCP, no change control, no audit trail. FDA inspectors are starting to notice.

The Platform

One platform.
The entire validation lifecycle.

From first requirement to post-market governance — every step compliant, auditable, and powered by AI that knows GAMP 5.

📄

Validation Factory

Generate GAMP 5-compliant URS from plain English. SMART refinement, PCCP verification, UR/FR decomposition, CSA test scripts, and PDF export with e-signature — in one guided workflow. What took days takes minutes.

URS Generation SMART Refinement UR/FR Decomposition CSA Test Scripts PDF + E-Signature
🔄

Change Control

ServiceNow change requests cross-referenced against your system portfolio in real time. GxP classification, GAMP-aware risk calculation using Severity × Occurrence × Detectability, and automatic revalidation flags. No spreadsheet required.

ServiceNow Integration GxP Classification GAMP Risk Matrix Revalidation Flags
🤖

AI Model Governance

Validated AI models treated as GAMP Category 5 assets. PCCP-aware change assessment aligned to FDA final guidance August 2025. Human-in-the-loop approval queue with 21 CFR Part 11 compliant audit trail.

PCCP Assessment HITL Governance FDA Aug 2025 21 CFR Part 11
📊

Portfolio Dashboard

Every system, every site, every phase — one view. RAG status, action items, regulatory due dates. Register new systems with GxP classification and track their full validation journey from plan to monitor. Built for QA Heads and CTOs.

RAG Status System Registry Lifecycle Tracking Multi-Site

See It In Action

Watch EVOLV handle in 4 minutes
what takes your team weeks.

Three real workflows. No voiceover scripts. No slides. Just the platform doing what it's built to do.

Demo 01

Portfolio Dashboard

Your entire validated system landscape — GAMP category, GxP status, risk level, revalidation due dates — in one view. Built for QA Heads and CTOs who need portfolio-wide compliance visibility instantly..

Demo 02

Change Control & GxP Classification

ServiceNow CR received → portfolio cross-reference → GAMP risk calculation → revalidation decision. Automatic.

Demo 03

AI Model Governance

AI model change in a validated system → PCCP assessment → Governance Hub → human-in-the-loop approval → 21 CFR Part 11 audit trail. Built for FDA's final guidance (Aug 2025).

Try the Validation Factory — live, right now.

Generate a real GAMP 5-compliant URS from your own requirement. No login required.

▶ Open Live Demo

Built For

EVOLV speaks the language
of regulated industries.

Whether you're defending a validation package in an inspection or governing 150 systems across 25 sites — EVOLV gives you the records to back it up.

🧪 QA Head · CSV Manager

Stop writing in Word. Start validating.

EVOLV generates, verifies, and manages your entire validation portfolio with a complete audit trail FDA inspectors can review on the spot.

  • URS from plain English in minutes
  • SMART requirements, auto-verified against GAMP 5
  • Full lifecycle tracking — Plan to Monitor
  • Audit-ready PDFs with e-signature

📋 VP Regulatory Affairs

FDA updated the rules. EVOLV already knows.

QMSR is mandatory. PCCP guidance is final. EVOLV cites the right regulations, routes the right changes, and produces the records you need when an inspector walks in.

  • Aligned to FDA PCCP Guidance Aug 18, 2025
  • 21 CFR Part 820 QMSR / ISO 13485:2016
  • SHA-256 tamper-evident audit trail
  • 21 CFR Part 11 electronic records

💻 CTO · CDO

Your AI models are GAMP Cat 5 assets.

EVOLV gives you the governance infrastructure to deploy AI in GxP contexts without regulatory exposure — with a full HITL approval layer and immutable decision records.

  • AI model registry with version history
  • PCCP-aware change assessment
  • Human-in-the-loop governance hub
  • Portfolio-wide RAG visibility

Regulatory Coverage

GAMP 5 (2nd Edition) 21 CFR Part 11 21 CFR Part 820 QMSR ISO 13485:2016 FDA PCCP Guidance Aug 18, 2025 GMP Annex 11 EU GMP GLP ISO 17025 GDPR 21 CFR Part 820.35 QMSR FDA CSA Guidance 2022

Early Access

Join our first cohort of life sciences partners.

We're working with a small group of pharma and biotech companies before general availability. Early access partners get priority onboarding, direct access to the founding team, and founding-tier pricing locked in permanently.

🔒  We'll respond within 1 business day. Your information is never shared.

How Data Analytics is Revolutionizing Biotech Consultancy

Sep 07, 2025

The Impact of Data Analytics on Biotech Consultancy

The integration of data analytics into biotech consultancy is reshaping the landscape of the industry. As biotechnology companies strive to innovate and remain competitive, the use of advanced data analytics tools has become an essential component of their strategic decision-making processes. By leveraging large datasets, biotech consultants can provide insights that were previously unattainable, paving the way for groundbreaking discoveries and more efficient business operations.

data analytics biotech

Enhanced Decision-Making Capabilities

Data analytics empowers biotech consultancies by enhancing their decision-making capabilities. With access to vast amounts of data, consultants can identify patterns, trends, and anomalies that inform strategic planning and risk management. This enables biotech companies to make informed decisions, minimize uncertainties, and increase their chances of success in a competitive market.

Furthermore, predictive analytics allows consultants to forecast future trends and outcomes. By analyzing historical data, they can develop models that predict market behavior, patient responses to treatments, and potential regulatory changes. This foresight is invaluable for biotech companies looking to stay ahead of the curve.

Accelerating Drug Development

One of the most significant impacts of data analytics in biotech consultancy is its ability to accelerate drug development. Traditional methods of drug discovery are often time-consuming and costly. However, with data analytics, consultants can streamline this process by identifying promising compounds faster and more efficiently.

drug development

By analyzing large datasets from clinical trials and patient records, consultants can identify potential correlations and causations that may not be immediately apparent. This can significantly reduce the time it takes to bring a new drug to market, ultimately benefiting patients and healthcare providers alike.

Improving Patient Outcomes

Data analytics also plays a crucial role in improving patient outcomes. Biotech consultancies utilize data to tailor treatments to individual patients, leading to more personalized and effective therapies. By analyzing patient data, including genetic information and medical history, consultants can recommend treatments that are more likely to succeed.

This personalized approach not only enhances patient care but also reduces healthcare costs by minimizing trial-and-error prescriptions. It represents a shift towards precision medicine, where treatments are optimized for individual patients rather than a one-size-fits-all approach.

patient outcomes

Navigating Regulatory Challenges

The biotech industry is heavily regulated, and navigating these regulations can be challenging. Data analytics assists biotech consultancies in understanding and complying with complex regulatory requirements. By analyzing regulatory trends and historical compliance data, consultants can provide guidance on best practices and potential pitfalls.

This proactive approach helps biotech companies avoid costly delays and ensures that their products meet regulatory standards. It also facilitates smoother interactions with regulatory bodies, further enhancing the company's reputation and credibility.

The Future of Biotech Consultancy with Data Analytics

As data analytics continues to evolve, its impact on biotech consultancy will only grow stronger. The integration of artificial intelligence and machine learning into data analytics tools promises even greater insights and efficiencies. Biotech consultancies that embrace these advancements will be well-positioned to lead the industry into the future.

Ultimately, data analytics is revolutionizing biotech consultancy by providing powerful tools for decision-making, accelerating drug development, improving patient outcomes, and navigating regulatory challenges. As the industry continues to evolve, the role of data analytics will undoubtedly become even more critical in shaping its success.